ROBOSENSE
3.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense , the world’s leading autonomous driving LiDAR perception solution provider , announced today that the solid-state LiDAR RS-LiDAR-M1Simple(Simple Sensor Version ) is now ready for customer delivery, priced at $1,898 . The new RS-LiDAR-M1Simple is less than half the size of the previous version, with dimensions of 4.3” x 1.9” x 4.7” (110mm x 50mm x 120mm), and is equipped with enhanced hardware performance virtually equal to the serial production version provided to OEMs. The main body design of this automotive-grade solid-state LiDAR is finalized and ready for shipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200103005139/en/
In addition, RoboSense will demonstrate the world’s first smart solid-state LiDAR, the RS-LiDAR-M1Smart (Smart Sensor Version), at CES 2020 in Las Vegas, Booth 6138, LVCC North Hall from Jan 7-10, 2020 with an on-vehicle public road test. The RS-LiDAR-M1Smart main body is embedded with an AI perception algorithm that fully takes advantage of LiDAR’s potential to transform conventional 3D LiDAR sensors to a full data analysis and comprehension system.
“The RS-LiDAR-M1 is an optimal choice for the serial production of self-driving cars, far superior to mechanical LiDAR. The sooner solid-state LiDAR is used, the sooner production will be accelerated to mass-market levels,” said Mark Qiu, RoboSense COO.
RS-LiDAR-M1 Family Features:
- 125 laser beams with exceptional performance: the RS-LiDAR-M1 has a field of view of 120°*25°, which is the MEMS solid-state LiDAR’s largest field of view among released products worldwide. RoboSense uses 905nm lasers with low cost, automotive grade and small size instead of expensive 1550nm lasers. At the same time, RoboSense continuously breaks ranging ability limits to 150m at 10% NIST target, which is also MEMS solid-state LiDAR’s longest detection range.
- World’s smallest MEMS solid-state LiDAR: one-tenth the size of conventional 64-beam mechanical LiDAR. The RS-LiDAR-M1 can be easily embedded in the car’s body while still maintaining the vehicle’s appearance intact.
- Reduced parts from hundreds to dozens in comparison to traditional mechanical LiDARs for lower cost, shorter production time, and large-scale production capacity .
- Modular design: the scalability and layout flexibility of the optical module lay the foundation for subsequent MEMS LiDAR products and support the customization of products for different application cases.
- Stable and reliable: RoboSense fully implemented IATF16949 quality management system and ISO26262 functional safety standards, combining ISO16750 test requirement and other automotive-grade reliability specifications to verify the RS-LiDAR-M1 series of products.
- All-weather: In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the standards, and the final mass-produced RS-LiDAR-M1 will adapt to all climatic and working conditions.
- Minimal wear and tear: as a solid-state LiDAR, the RS-LiDAR-M1 eliminates potential optoelectronic device failures due to mechanical rotation.
The RS-LiDAR-M1Smart is a comprehensive system with sensor hardware, AI point cloud algorithm, and chipsets, which provides an end-to-end customer environment perception solution. RoboSense’s powerful AI perception algorithm injects the sensor with structured semantic-level comprehensive information, focusing on the perception of moving objects.
For orders visit www.robosense.ai/buy or to contact a RoboSense account manager.
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, Samsung, ControlWorks, Aidrivers, and more. For more information, see the website at: http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005139/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom